Home Cart Sign in  
Chemical Structure| 882366-16-7 Chemical Structure| 882366-16-7

Structure of SBI-115
CAS No.: 882366-16-7

Chemical Structure| 882366-16-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SBI-115 is a GPBAR1 (TGR5) antagonist.

Synonyms: SBI-115

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SBI-115

CAS No. :882366-16-7
Formula : C14H13ClN2O4S
M.W : 340.78
SMILES Code : O=S(C1=NC=C(Cl)C(C(OC2=CC(C)=CC=C2)=O)=N1)(CC)=O
Synonyms :
SBI-115
MDL No. :MFCD07537427
InChI Key :IJPXOPBVXVPPEW-UHFFFAOYSA-N
Pubchem ID :18879973

Safety of SBI-115

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SBI-115

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
ADPKD human cystic cholangiocytes 100 and 200 µM 24 hours To evaluate the effect of SBI-115 on cholangiocyte proliferation, results showed that SBI-115 inhibited TLCA-induced proliferation in a dose-dependent manner Hepatology. 2017 Oct;66(4):1197-1218.
PCK rat cystic cholangiocytes 100 and 200 µM 24 hours To evaluate the effect of SBI-115 on cholangiocyte proliferation, results showed that SBI-115 inhibited TLCA-induced proliferation in a dose-dependent manner Hepatology. 2017 Oct;66(4):1197-1218.
RAW264.7 cells 100 µM 24 hours SBI-115 inhibited the effect of SB on expression of TGR5 and β-arrestin2 induced by LPS Mol Med. 2025 Jan 29;31(1):31.
RAW264.7 cells 1 µM 48 hours SBI-115 inhibited the osteoclast differentiation-suppressing effect of SPN on RAW264.7 cells Drug Des Devel Ther. 2025 Mar 6;19:1595-1608.
BMSCs 1 µM 48 hours SBI-115 inhibited the osteogenic differentiation-promoting effect of SPN on BMSCs Drug Des Devel Ther. 2025 Mar 6;19:1595-1608.
BXPC3 cells 5 µM 48 hours To evaluate the effect of SBI-115 on BXPC3 cell proliferation, results showed that SBI-115 significantly inhibited cell proliferation and induced apoptosis Discov Oncol. 2022 Jun 11;13(1):46.
PANC-1 cells 10 µM 48 hours To evaluate the effect of SBI-115 on PANC-1 cell proliferation, results showed that SBI-115 significantly inhibited cell proliferation and induced apoptosis Discov Oncol. 2022 Jun 11;13(1):46.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
DBA/1J mice Collagen-induced arthritis (CIA) model Oral 80 mg/kg Daily administration for 28 days SBI-115 eliminated the benefits of B. pseudocatenulatum mediated by TGR5 immune response Nutrients. 2023 Jan 4;15(2):255

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.93mL

0.59mL

0.29mL

14.67mL

2.93mL

1.47mL

29.34mL

5.87mL

2.93mL

 

Historical Records

Categories